A 17-year-old male with chronic myelogenous leukemia in blast crisis received a non-T cell-depleted (TCD) HLA haplo-identical three-loci mismatched hematopoietic stem cell transplant (HSCT) from his mother. Long-term feto-maternal microchimerism was detected by nested polymerase chain reaction with sequence-specific primer typing. The post-transplantation prophylaxis against graft-versus-host disease (GVHD) was tacrolimus with minidose methotrexate. Sustained engraftment was obtained. Acute GVHD (grade 2) developed, but improved rapidly. Bone marrow aspiration on day 120 showed complete remission. Non-TCD HLA haplo-identical HSCT based on feto-maternal microchimerism might be feasible and has important implications in the selection of alternative family donors in HSCT.
family donors who were HLA partially-matched with the recipients was unsuccessful because of graft failure and severe graft-versus-host disease (GVHD). 1 To prevent graft failure and severe GVHD in these patients, T-cell depletion (TCD) from the graft was established and succeeded in reducing GVHD, but often with a high incidence of graft failure, infection and leukemia relapse. 2 Allogeneic CD34 + cell transplantation has been used as an alternative to TCD, but the results of previous studies in HLA-mismatched HSCT have not been consistent in terms of incidence severe GVHD and relapse rate of leukemia being high in highrisk patients. 3 During the reproductive period, the immune system of the fetus is exposed to non-inherited maternal antigens (NIMA), while that of the mother is exposed to inherited paternal antigens of the fetus, possibly establishing immunological tolerance between the mother and fetus. The existence of fetal hematopoietic cells in maternal blood and vice versa, known as feto-maternal microchimerism, supports this concept. 4 The role of feto-maternal immunological tolerance has recently been reported in allogeneic renal transplants and HSCT. [5] [6] [7] Tamaki et al 6 demonstrated a superior outcome for maternal as opposed to paternal donations in HSCT using the database of a nationwide HSCT survey in Japan. Van Rood et al 7 also showed that recipients of non-TCD maternal transplants had a significantly lower incidence of acute and chronic GVHD than did recipients of paternal transplants in haplo-identical transplants. Based on these observations, we report a successful non-TCD HLA haplo-identical three-loci mismatched HSCT from mother to son in a case of blast crisis of chronic myelogenous leukemia (CML). This case is the first report of successful non-TCD HLA haplo-identical three-loci mismatched HSCT and has important implications in the selection of alternative family donors in HSCT.
Case report
A 17-year-old male was admitted to hospital in April 2001 with fever and dyspnea. Physical examination showed ane- The patient received hydroxycarbamide, but his condition deteriorated rapidly. Two courses of the VP (vincristine and prednisolone) regimen, doxorubicin, vincristine and cytarabine also failed to delay disease progression; the bone marrow was hypocellular with 28.6% blast cells in May 2001, and he was diagnosed as having CML in blast crisis. Allogeneic HSCT was planned, but he lacked an HLA-identical sibling donor. A few HLA-identical donors were found in the unrelated bone marrow donor bank of Japan, but body weight imbalances and schedule disagreements prevented their use. Cord blood registries failed to find donors HLA-mismatched within two-loci and with a sufficient number of nucleated cells. We therefore decided on an HLA haplo-identical HSCT from the mother based on the hypothesis of feto-maternal immunological tolerance. The patient and his mother had a three-loci HLA mismatch in the GVHD direction (Table 1a) . Minor histocompatibility antigens (mHA) were matched for CD31, CD49b, CD62L and HA-1 8 (Table 1b) . The lymphocyte crossmatch test was negative. HLA-nested polymerase chain reaction with sequence-specific primer typing (PCR-SSP) demonstrated the IPA of the patient to be present in the peripheral blood of the mother with NIMA in the peripheral blood of the patient, suggesting the existence of long-term feto-maternal microchimerism in the peripheral blood mononuclear cells of both individuals (Figure 1 ). After obtaining ethical committee agreement from our hospital and written informed consent from the patient and his parents, we performed an HLA haplo-identical HSCT without TCD or selected CD34 + cell transplantation. His mother Minor histocompatibility antigens (mHA)
L, leucine; V, valine; N, asparagine; E, glutamic acid; P, proline; H, histidine. a HLA was a three-loci mismatch at A, B and DR serologically between the recipient and donor. b Minor HA was matched in CD31, CD49b, CD62L and HA-1 between the recipient and donor.
was given filgrastim at a dose of 300 g/m 2 subcutaneously for 5 days and PBSC were collected from day 4 to day 6 using a continuous blood cell separator (CS3000, Fenwall), but a total of only 1.0 ϫ 10 6 /kg CD34 + cells were harvested. Therefore, we combined PBSC and bone marrow for the allogeneic HSCT.
The patient received conditioning with cytarabine (CA) 2 g/m 2 twice on day Ϫ6 and once on days Ϫ5 and Ϫ4, cyclophosphamide (CY) 60 mg/kg on days Ϫ4 and Ϫ3, and total body irradiation 2.5 Gy twice on days Ϫ2 and Ϫ1. GVHD prophylaxis consisted of tacrolims and minidose methotrexate, as described previously. /l on day 21 and a platelet count Ͼ50 ϫ 10 9 /l on day 28. Acute GVHD grade 2 (skin, stage 2; liver, stage 0; gut, stage 1) occurred on day 21, but improved rapidly using prednisolone 2 mg/kg/day. Karyotypic analysis by G-banding showed 46,XX in all metaphase cells analyzed, and FISH analysis of bone marrow mononuclear cells revealed that the fusion signal for the bcr-abl gene was decreased to within normal limits, and over 98% of sex chromosomes had changed to XX on days 30, 60, 90 and 120.
Discussion
Based on the hypothesis that the existence of immunological tolerance between a mother and her child gives rise to a form of actively acquired bilateral tolerance which is maintained even after the pregnancy, we performed an HLA haplo-identical three-loci mismatched HSCT from mother to son without TCD or CD34
+ cell selection in a patient with CML in blast crisis. Engraftment was stable and the patient achieved complete remission. Only acute GVHD (grade 2) developed, but improved rapidly.
Recently, by using a highly sensitive PCR for Y-chromosome-specific or HLA-specific DNA, several groups have demonstrated the long-term presence of fetal CD34 + CD38
+ progenitor cell and multi-lineage fetal hematopoietic cell microchimerism in postpartum maternal blood. 4 In our case, PCR-SSP demonstrated the existence of maternal 7 also demonstrated that recipients of non-TCD maternal transplants had a significantly lower incidence of chronic GVHD than did recipients of paternal transplants (P Ͼ 0.02) by analyzing 319 patients of one-or two-HLA mismatched sibling and maternal or paternal transplants for leukemia. These observations suggested that the long-term feto-maternal microchimerism might be an indicator of persistent fetomaternal immunological tolerance. The lack of severe GVHD in our case was considered to result not only from the existence of tolerance to NIMA, but also the matched mHA and the use of tacrolims. [8] [9] [10] In addition, the patient has continued in complete remission after transplantation despite blast crisis of CML although the follow-up period is short. In this context, Tamaki et al 6 demonstrated that the risk of relapse of malignant hematological disease was not significantly different between recipients with maternal Bone Marrow Transplantation or paternal donors. This suggested that any allogeneic graftversus-leukemia/lymphoma effect was not influenced by maternal tolerance to fetal histocompatibility antigens. Further study is warranted to clarify this issue.
In conclusion, we succeeded in undertaking an HLA haplo-identical three-loci mismatched HSCT without TCD or selected CD34
+ cell transplantation based on fetomaternal immunological tolerance, which was confirmed by the long-term feto-maternal microchimerism, this being the first successful report. HLA haplo-identical HSCT with feto-maternal microchimerism may provide a further chance of HSCT in patients with hematological malignancies who lack an HLA-identical donor, and this case has important implications in the selection of alternative familial donors for HSCT.
